Dividends Calendar Earnings Calendar
NERV

NERV | Minerva Neurosciences Inc

Healthcare sector
Minerva Neurosciences Inc

Company profile

  • Industry: Biotechnology
  • Sector: Healthcare
  • Headquarters:   Waltham, Massachusetts, United States
  • Number of employees::   11
Investor Relations : ir.minervaneurosciences.com

Company profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's portfolio of compounds includes: Roluperidone (MIN-101) in Phase 3 clinical  development for schizophrenia; a potential royalty stream from Seltorexant (MIN-202 or JNJ 42847922), in clinical development for insomnia and major depressive disorder (MDD); and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."

  • Subsidiaries:   Subsidiary: Mind-NRG SA

Address

1601 Trapelo Road
Suite 286
Waltham, MA 02451
United States

Products & Services

  • Roluperidone (MIN-101)

  • Seltorexant (MIN-202)

  • MIN-117

  • MIN-301



    Jump to (Finance sites)

    Google     
             

    Research 


    Investor page

    ir.minervaneurosciences.com

    If you are looking for News & events, Press Release, they are available on their Investors Relationssite.


    Consensus
    BUY 100
    HOLD 0
    SELL 0

    Their Official Profiles 

    LinkedIn

    Support this project

    If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
    More features coming soon :)

    Social Media 




    Recommended Books

    The Internet of Money
    Buy on Amazon

    While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology.